参麦注射液治疗病毒性心肌炎的Meta分析

Shenmai Injection for treatment of viral myocarditis:a Meta-analysis

目的评价参麦注射液治疗病毒性心肌炎的临床疗效及安全性。方法检索中国生物医学文献数据库(CBM)、中国期刊全文数据库、中国优秀硕士学位论文全文数据库、中国博士论文全文数据库、中文科技期刊数据库(维普)、万方数据资源系统等文献数据库,对符合纳入标准的随机对照试验进行Meta分析。结果共纳入12篇临床研究。与对照组相比,参麦注射液治疗组可显著提高临床治疗有效率[RR=1.22,95%CI(1.14,1.30),P<0.000 01]。结论参麦注射液可显著提高病毒性心肌炎患者的临床疗效,并未见明显不良反应,但由于国内中药研究整体质量有待提高,尚需进行进一步高质量随机对照试验加以证实。

AIM To assess the clinical efficacy and safety of Shenmai Injection in the treatment of viral myocarditis.METHODS All randomized controlled trials（RCTs） of Shenmai Injection with viral myocarditis were searched from CBM,CNKI,VIP and Wanfang Data.After being selected according to some rules,a meta-analysis was performed on the recruited RCTs with the Cochrane Collaboration＇s RevMan 5.1 and Stata 10.0.RESULTS A total of 12 RCTs were collected in this analysis.The effective rate of Shenmai Injection group was better than that of the control group（RR=1.22,95%CI： 1.14-1.30,P0.000 01）.CONCLUSION The analysis shows that Shenmai Injection can increase the clinical efficacy of viral myocarditis.While the quality of included RCTs is not good enough,more high-quality RCTs need to be done in the future.